Elekta AB (SE:EKTA.B)
:EKTA.B
Want to see SE:EKTA.B full AI Analyst Report?
Top Page
Elekta AB
(EKTA.B)
Select Model
Select Model
Rating:53Neutral
Price Target:
kr48.00
▼(-15.72% Downside)
Action:Reiterated
Date:05/29/26
The score is held back primarily by deteriorating profitability (net loss and lower EBIT) and a weakened equity base, despite strong and improving free cash flow. Technicals are also a headwind with the stock below key moving averages and overbought-leaning oscillators. Valuation is mixed: a solid dividend yield helps, but a negative P/E reflects the loss-making year.
Positive Factors
Strong free cash flow
Sustained high operating cash flow and a large jump in free cash flow give Elekta durable flexibility to service debt, fund R&D, and finance capital equipment cycles. Strong FCF supports reinvestment in product upgrades and long-term service capabilities despite reported accounting losses.
Negative Factors
Swing to net loss
A sharp deterioration to a substantial net loss and a halving of EBIT weakens internal funding capacity and may reflect one-offs or structural margin pressure. Persistent losses can limit reinvestment, constrain pricing power, and make long-term planning and dividends more difficult.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong free cash flow
Sustained high operating cash flow and a large jump in free cash flow give Elekta durable flexibility to service debt, fund R&D, and finance capital equipment cycles. Strong FCF supports reinvestment in product upgrades and long-term service capabilities despite reported accounting losses.
Read all positive factors
Elekta AB (EKTA.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr18.41B
Dividend Yield4.25%
Average Volume (3M)1.33M
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue Growth-7.22%
EPS Growth-317.94%
CountrySE
Employees4,541
SectorGeneral
Sector StrengthN/A
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-1.35
Shares Outstanding368,587,650
10 Day Avg. Volume896,136
30 Day Avg. Volume1,329,676
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.88
Price to Sales (P/S)1.22
P/FCF Ratio8.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr48.38Price Target Upside-15.06% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering4
EPS Forecast (FY)3.87
Revenue Forecast (FY)kr17.24B
Elekta AB Business Overview & Revenue Model
Company Description
Elekta AB (publ) operates as a global medical technology company, delivering advanced clinical solutions for managing cancer and various brain disorders. Its extensive oncology offerings include sophisticated radiation therapy systems such as Vers...
How the Company Makes Money
Elekta primarily makes money by selling radiation therapy equipment and associated software to hospitals, cancer centers, and other healthcare providers. A major revenue stream comes from system sales (capital equipment such as linear accelerators...
Elekta AB Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
55
Neutral
Cash Flow
72
Positive
| Breakdown | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 16.72B | 18.02B | 18.12B | 16.87B | 14.55B |
| Gross Profit | 6.25B | 6.75B | 6.80B | 6.35B | 5.44B |
| EBITDA | 1.68B | 2.19B | 3.29B | 2.57B | 2.69B |
| Net Income | -520.00M | 237.00M | 1.30B | 943.00M | 1.15B |
Balance Sheet | |||||
| Total Assets | 26.95B | 28.98B | 31.41B | 29.61B | 26.30B |
| Cash, Cash Equivalents and Short-Term Investments | 3.19B | 2.96B | 2.78B | 3.27B | 3.07B |
| Total Debt | 7.33B | 7.57B | 7.25B | 6.67B | 5.70B |
| Total Liabilities | 19.81B | 20.13B | 20.63B | 19.88B | 17.39B |
| Stockholders Equity | 7.10B | 8.80B | 10.78B | 9.73B | 8.91B |
Cash Flow | |||||
| Free Cash Flow | 2.34B | 1.06B | 817.00M | 400.00M | 450.00M |
| Operating Cash Flow | 2.46B | 2.63B | 2.46B | 1.96B | 1.86B |
| Investing Cash Flow | -1.07B | -1.67B | -1.92B | -1.61B | -1.65B |
| Financing Cash Flow | -1.17B | -607.00M | -1.10B | -129.00M | -1.73B |
Elekta AB Technical Analysis
Negative
56.95
Price Trends
54.76
Negative
55.16
Negative
52.95
Negative
Market Momentum
-2.25
Positive
32.51
Neutral
11.20
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:EKTA.B, the sentiment is Negative. The current price of 56.95 is above the 20-day moving average (MA) of 51.50, above the 50-day MA of 54.76, and above the 200-day MA of 52.95, indicating a bearish trend. The MACD of -2.25 indicates Positive momentum. The RSI at 32.51 is Neutral, neither overbought nor oversold. The STOCH value of 11.20 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:EKTA.B.
Elekta AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | kr33.05B | 47.95 | 20.86% | ― | 10.03% | 22.96% | |
72 Outperform | kr7.19B | 32.08 | 24.30% | 1.32% | 2.87% | 0.24% | |
69 Neutral | kr7.74B | 34.18 | 15.16% | ― | 18.06% | 10.57% | |
64 Neutral | kr1.26B | 42.40 | 6.93% | ― | -8.92% | -8.33% | |
58 Neutral | kr12.14B | -2.42 | 3.34% | 0.80% | -5.68% | -1106.19% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | kr18.41B | -35.59 | 3.08% | 4.25% | -7.22% | -317.94% |
* General Sector Average
SE:EKTA.B
Elekta AB
48.18
1.59
3.42%
SE:VITR
Vitrolife AB
89.65
-48.92
-35.31%
SE:CAMX
Camurus AB
551.00
-55.50
-9.15%
SE:RAY.B
RaySearch Laboratories AB
209.80
-118.26
-36.05%
SE:CRAD.B
C-Rad AB Class B
37.20
1.36
3.79%
SE:MCAP
MedCap AB
513.00
65.00
14.51%
Elekta AB Corporate Events
Elekta Sets Mid‑Term Profitability Targets and 2026/27 Outlook Ahead of Capital Markets Day
Jun 17, 2026
Elekta has unveiled new mid‑term financial targets and a detailed outlook for fiscal 2026/27, outlining a strategy to boost profitability and long‑term growth through focused innovation, a new operating model and clearer regional strat...
Elekta Nomination Committee Proposes Board Line-up and New Director for 2026 AGM
Jun 12, 2026
Elekta’s Nomination Committee has proposed the re-election of nine current board members, including Chair Laurent Leksell, and the election of Sandvik CFO Cecilia Felton as a new director for the term ending at the next annual general meetin...
Elekta lifts margins and cash flow despite impairments and lower sales
May 28, 2026
Elekta reported a marginal 1% rise in full-year net sales at constant exchange rates, but a 7% decline in reported SEK sales, as emerging-market weakness offset growth in China and EMEA. Despite lower revenue and substantial non-cash impairments t...
Elekta Showcases MR-Guided Radiotherapy Breakthroughs at ESTRO 2026
May 18, 2026
Elekta unveiled new clinical research at the ESTRO 2026 congress showcasing advances in MR-guided adaptive radiotherapy across multiple cancer types, including prostate, rectal and liver metastases. The findings underscore how real-time imaging wi...
Elekta Schedules Webcast for Fiscal 2025/26 Year-End Results
May 13, 2026
Elekta has invited analysts and investors to a webcast presentation of its fiscal year 2025/26 results on May 28, with the year-end report to be released earlier that morning. CEO Jakob Just-Bomholt and CFO Klara Eiritz will present the company...
Elekta Sets June Capital Markets Day to Outline Strategy and Financial Targets
Apr 17, 2026
Elekta will host a Capital Markets Day on June 17, 2026, in Stockholm, inviting investors, analysts and other stakeholders to attend in person or online. The company plans to outline its strategy and financial targets, with CEO Jakob Just-Bomholt,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.